Solid recap. All they have to do is Make os avail through transfer agent. Some otc companies even do daily/weekly now.. In this day and age. To not have that makes no sense. They Talk about all these rules to protect retail and we don’t know what os is. We Have to guess. Wild

Thanks. I read bunch stuff too could not pin down as I have several of these. Just curious how long they have . Eternity or not, lol. All the best

Anyone know if there is a hard deadline with no quotes that would lead to Revocation. Is it 2 quarters, 1 year or no deadline

I get science and accounting are vastly separate. But, I would certainly Google the company and trial to learn about it. Sec delinquent expert market black diamonds . Why not, Sign me up lol

1,000 share trade. . We are officially down 99% on the day from .0001 Wild stuff

Such a Complicated stock. It’s all about acquisitions for me They surrounded by power players. Getting funding at .01. Ceo owns stake in amazing ev startup. Pr even mentioned looking at massive acquisitions up to 50m. Probably Why someone put up 1m .01. But in all my years that preferred with discovery one of worst things I’ve ever seen. Show me that is cleared up and I think
Good chance at mega acquisitions and mega run based on who they linked up with

Previous Funding PR. What does anyone know about this relationship. THis company has represented some massive deals. Including EV related
https://clearthink.capital

https://www.otcmarkets.com/stock/BYOC/news/story?e&id=2031636

Contact Information:

investors@beyondcommerceinc.com
p702-675-8022
ClearThink
nyc@clearthink.capital

SOURCE: Beyond Commerce, Inc.

Past represented PR

Nasdaq CO https://www.globenewswire.com/en/news-release/2021/09/30/2306346/0/en/Paltalk-Inc-Engages-ClearThink-to-Lead-Expanded-Investor-Relations-Program.html

If they can settle with discover, probable one of best .000 setup stocks right now imo. Ceo Major connections to serious ev and capital. And I have my own bias on this ticker through the years. But if you look at players involved it’s mind boggling

Awesome! Here they come

One of my biggest concerns was just missing part of the bull wave. I know that’s probably not a huge factor for multi year future holders. But too much potential here not reward current holders. That said, we might be entering a crescendo period. I’m in awe some of price action I’m seeing. Get current and drop a big partnership deal anything possible. Timing is good!!

Yeah. I won’t post anymore examples. Keep talk on crxm . But wanted to show board how fast some are coming off expert . I believe crxm per email fins coming very soon

Sec delinquent with unaudited fins seem to be just slapping as pink current with quotation almost right away .

As relates to crxm
https://www.otcmarkets.com/stock/GFTX/disclosure

Continue to see more and more easily peel off expert . File fins today and we could be off expert this week

Enjoy the weekend Bentleyt. All the best to crxm holders. Well Deserving bunch for a run after this wild year/day.

This stock as it relates to crxm expert to pink. Quick turn around once fins posted

https://www.otcmarkets.com/stock/WGEI/disclosure

Fascinating! Nice break down

I am now seeing companies like crxm come off expert market. Simply get filings in. Could be like butter . Get filings in

Yeah. I was just marveling at the uniqueness of situation with the ever slightest side of humor. Blips can happen both ways. Let’s see 270 share 300x tomorrow

Not sure I’ve ever closed down 99.7% this is first. Maybe we get massive bounce tomorrow of this support.

I know a Handful filed audited 10-12g. I believe they are coming back in time. But these can take 60 days. Will get a sponsor for quotation. What’s unreal is Canadians are still trading these. It’s a competitive disadvantage.

Nostrum funding May 2020. It was the pandemic, no doubt. So some leeway. But this was one of most important items. 16months they had. I don’t even need to comment further . We all know it should have been done. Be extent of my criticism as does no good bemoaning it. I think they will get current . Will almost certainly take audited financials now.

To be fair I said .0018 “plus”. So I’m open to it

Yeah, One would think that's enough for .0018 plus. 24 mil cash flow positive with more acquisitions this quarter. Will see

https://www.otcmarkets.com/stock/NECA/news/David-Fair-Named-in-2021-Wood-Industry-40-Under-40?id=313342

They have also helped the turnaround of two companies from break-even to double-digit cash flow margins

Been in this now few times. If ceo plainly said os was reasonable or nearly same I would go in this area big time. Maybe it will bounce/run regardless. But that is truly an unknown now. Real risk factor. What if os is double. Equivalent of 2.80 price right now.

Solid burn branch. I held several to the expert market. So far it’s working pretty good as I don’t have to do anything. lol. All jokes aside, the ones that did make it right before the buzzer practically 10x already. so that’s why I had to decide to hold certain ones knowing risk or sell for peanuts. Now I just had an expert file an audited 10-12g the other day. One by one some of these experts could come roaring back. A few won’t. But the mega runs offset dumping them all for peanuts. The ones that come back could be given special attention. We shall see

Wild day, but there is substance here. Could be largest revenue. Co under .002 with more acquisitions planned for years end in hyperbolic otc market . We shall see


What is the run rate for 2021?
With our current operations we expect to be at about $24M of combined revenue for 2021. However, we have several synergistic acquisitions in the pipeline that we anticipate completing before the end of the year.


https://www.otcmarkets.com/stock/NECA/news/Third-Bench-Q--A-From-Emerging-Growth-Conference-Highlights?id=318379

Have 10 people with 10 different strategies. Do what works for you. I have respect altitrade long ball strategy. If it works massive payday. And he’s hit some before with that strategy. The biggest risk I see to that strategy is funding. By time they Complete phase 3 I have no idea what crxm looks like. Share structure ect. But respect the plan. All we can do is watch it play out.

My take is they never really gave deadline In that letter. Just stated fins are coming and tech they are in compliance per rule as of right now. But, otcmarkets seems to be running their own operation however they choose. Never seen a private co related to stock with so much authority/ power . I know companies paid fees months ago for access and never got it. Who determines that/ due process. If crxm is right and they should be quoted it don’t matter because all brokers seem to be defaulting to otcmarkets. And they had crxm no information stop sign. Just have to watch how easy or tough it is for companies to come back . I’m waiting / watching for first one to come back as we speak. Who will it be

Technically deadline is over. Point of my post. I don’t know how easy or hard this will be from here. I have now just seen 2-3 sec reporting post more fins today post deadline. No idea if that’s enough or how rigorous steps will be. As I see comparable cos come back will share .

As it relates to CRXM, here is one just dropped remaining filings today. Fully reporting, unaudited, expert market. What will happen to it

https://www.otcmarkets.com/stock/BOXS/disclosure

Will just have to watch and see all the attempts to regain quotes across the otc and we will know real quick how easy or tough this is. I have heard both sides.

Expert market. https://www.otcmarkets.com/stock/CRXM/overview

If this is right. We should stay just like we are and not be sent to greys. But still limited buying as not fully current. But we are in compliance for quotations.

Technically they made the deadline and I agree, But watch this not be good enough. And I’m normally very optimistic but I’ve had with this embarrassing process. Everyone winging it. Brokers have Own cut off dates and Interpretation of rules.


Legal counsel has advised us that the recent filing of our Gene Biotherapeutics’ Quarterly Report on Form 10-Q for the period ended June 30, 2020 establishes Gene Bio’s compliance with the Rule, and that we would expect broker dealers to continue to post the bid and ask for CRXM until October 31, 2021.

I agree with his stance. Let’s see if those filings drop. Then we have to hope finra/otcmarkets/brokers act accordingly. Which, I have my doubts based on the three ring circus Ive witnessed. Brokers early deadlines, glitches , otcmarkets being a defective decider of things.

Absolute wild card on this play. We are completely in different class b vs common. I prefer to just speak as kindly as possible about nostrum. We want them to value us. They can do whatever they want here

Seeing on Twitter glitch fixed now . Wild

Wow. It is true. Cannot make this stuff up. I’m holding a decent core , I cannot buy anywhere. come on crxm bring the fins, all the best

I’m seeing on Twitter Schwab has glitch allowing buys on everything lol.

Yes, you got my main point. But, I also meant to post this snippet below. There is a couple sweet scenarios where they could get grant money, royalties or strategic partnerships. This would move the project forward and create more value for us and probably much better deals in the future once phase 3 moving along. It is a key item

he Company anticipates that negative cash flows from operations will continue for the foreseeable future. We have yet to generate positive cash flows from operations and we are essentially dependent on external funding sources to support the Company’s research, development and commercialization activities. The Company’s history of recurring losses and uncertainties as to whether operations will become profitable raises substantial doubt about its ability to continue as a going concern for the next twelve months from the date of issuance of these financial statements. We do not have any unused credit facilities. We intend to pursue sources of working capital from non-dilutive funding channels to support the Company’s operations that could include, but not be limited to, (1) up to $3.350 million from potential royalties from commercial sales of Excellagen® from certain geographic regions, including the United States; (2) Federal government sponsored research grants; (3) agreements and arrangements covering distributor and strategic partnerships and drug royalty agreements based on the commercial sale of Generx following the successful completion of the planned FDA-cleared, Phase 3 AFFIRM clinical study and FDA registration in the U.S., and additional registrations to market and sell Generx in other countries internationally. At the appropriate time, with favorable market conditions, and an appropriate enterprise value reflective of the Company’s clinical status and the Generx [Ad5FGF-4] economic potential, we could also consider the sale of equity and debt securities in a privately negotiated structured transactions or public capital market offerings.